Department of Surgery, College of Medicine, University of Bisha, P.O Box 551, 61922, Bisha, Saudi Arabia.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6417-6437. doi: 10.1007/s00210-024-03121-8. Epub 2024 May 1.
Natural products are chemical compounds produced by living organisms. They are isolated and purified to determine their function and can potentially be used as therapeutic agents. The ability of some bioactive natural products to modify the course of cancer is fascinating and promising. In the past 50 years, there have been advancements in cancer therapy that have increased survival rates for localized tumors. However, there has been little progress in treating advanced renal cell carcinoma (RCC), which is resistant to radiation and chemotherapy. Oncogenes and tumor suppressors are two roles played by microRNAs (miRNAs). They are involved in important pathogenetic mechanisms like hypoxia and epithelial-mesenchymal transition (EMT); they control apoptosis, cell growth, migration, invasion, angiogenesis, and proliferation through target proteins involved in various signaling pathways. Depending on their expression pattern, miRNAs may identify certain subtypes of RCC or distinguish tumor tissue from healthy renal tissue. As diagnostic biomarkers of RCC, circulating miRNAs show promise. There is a correlation between the expression patterns of several miRNAs and the prognosis and diagnosis of patients with RCC. Potentially high-risk primary tumors may be identified by comparing original tumor tissue with metastases. Variations in miRNA expression between treatment-sensitive and therapy-resistant patients' tissues and serum allow for the estimation of responsiveness to target therapy. Our knowledge of miRNAs' function in RCC etiology has a tremendous uptick. Finding and validating their gene targets could have an immediate effect on creating anticancer treatments based on miRNAs. Several miRNAs have the potential to be used as biomarkers for diagnosis and prognosis. This review provides an in-depth analysis of the current knowledge regarding natural compounds and their modes of action in combating cancer. Also, this study aims to give information about the diagnostic and prognostic value of miRNAs as cancer biomarkers and their involvement in the pathogenesis of RCC.
天然产物是由生物体产生的化学化合物。它们被分离和纯化以确定其功能,并可能被用作治疗剂。一些生物活性天然产物改变癌症进程的能力令人着迷且有希望。在过去的 50 年中,癌症治疗取得了进展,提高了局部肿瘤的生存率。然而,治疗对辐射和化疗有抵抗力的晚期肾细胞癌(RCC)几乎没有进展。癌基因和肿瘤抑制基因是 microRNAs(miRNAs)发挥的两个作用。它们参与缺氧和上皮-间充质转化(EMT)等重要的发病机制;它们通过涉及各种信号通路的靶蛋白控制细胞凋亡、细胞生长、迁移、侵袭、血管生成和增殖。根据其表达模式,miRNAs 可能识别出 RCC 的某些亚型,或区分肿瘤组织和健康肾组织。作为 RCC 的诊断生物标志物,循环 miRNAs 显示出前景。几种 miRNAs 的表达模式与 RCC 患者的预后和诊断相关。通过将原始肿瘤组织与转移灶进行比较,可能可以识别出潜在的高风险原发性肿瘤。治疗敏感和耐药患者组织和血清中 miRNA 表达的差异可用于估计对靶向治疗的反应性。我们对 miRNAs 在 RCC 发病机制中的功能的认识有了巨大的提高。寻找和验证它们的基因靶标可能会对基于 miRNAs 的抗癌治疗产生直接影响。几种 miRNAs 具有作为诊断和预后生物标志物的潜力。本综述深入分析了天然化合物及其在抗癌中的作用方式的现有知识。此外,本研究旨在提供有关 miRNAs 作为癌症生物标志物的诊断和预后价值及其在 RCC 发病机制中的参与的信息。